Lilly Prepares for Retatrutide FDA Filing Following Additional Phase 3 Data in Diabetes, CVD

The landscape of antiobesity pharmacotherapy is shifting from dual-hormone modulation to a triple-agonist approach that may finally rival the results of surgical intervention, according to positive topline results from TRIUMPH-2 (NCT05929079) and TRIUMPH-3 (NCT05882045), 2 pivotal phase 3 trials for retatrutide (Eli Lilly).¹

Retatrutide is an investigational triple hormone receptor agonist.^1,2 The first-in-class agent targets the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors, offering a unique metabolic profile that separates it from currently available dual-agonists, such as tirzepatide (Zepbound; Eli Lilly).¹

For the pharmacy community, these data represent a critical expansion of the evidence base, moving beyond simply obesity into populations with significant comorbidities—specifically type 2 diabetes (T2D) and established cardiovascular disease (CVD).

TRIUMPH-2: Overcoming the Diabetes Weight Loss Plateau

It has long been observed in clinical practice that patients with T2D struggle to achieve the same magnitude of weight loss as those without the condition. TRIUMPH-2 specifically addressed this challenge, evaluating 1152 adults with obesity or overweight and T2D. At 80 weeks, participants on the 12-mg dose of retatrutide achieved a mean weight reduction of 20.8% (49.6 Ibs) from a baseline average of 234.6 Ibs.¹

Beyond weight, the glycemic improvements were equally striking. Participants saw average hemoglobin A_1C reductions of up to 1.6%. Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, a professor of pharmacy practice at the Massachusetts College of Pharmacy, said in an interview with Pharmacy Times that retatrutide’s unique mechanism is central to these results. She explained that the drug’s glucagon receptor agonism provides an additional pathway of “increased hepatic fatty acid oxidation and energy expenditure that is absent in the other agents.” This metabolic “triple threat” appears to maintain a weight loss trajectory where other agents might plateau.¹

TRIUMPH-3: Targeting Severe Obesity and Cardiovascular Risk

Although weight loss is a primary goal, the ultimate utility of these agents lies in their ability to reduce long-term morbidity. TRIUMPH-3 focused on 1949 adults with severe obesity (body mass index [BMI] ≥35) and established cardiovascular disease. In this high-risk cohort, the 12-mg dose delivered a substantial weight loss of 22.6% (55.8 Ibs) at 80 weeks.¹

Crucially for pharmacists monitoring long-term safety, preliminary cardiovascular outcomes data were shared. Major adverse cardiovascular events (including all-cause death, myocardial infarction, stroke, heart failure, or revascularization) occurred in 44 participants on retatrutide compared to 52 in the placebo group, resulting in a hazard ratio of about 0.82. Additionally, retatrutide demonstrated robust improvements in several key cardiometabolic markers¹:

• Triglycerides: Reduced by 37%
• Non–high-density lipoprotein cholesterol: Reduced by 16.5%
• High-sensitivity C-reactive protein (hsCRP): Reduced by 51.2%
• Systolic blood pressure: Reduced by 9.3 mmHg

Goldman highlighted the significance of the hsCRP reduction, noting that, “…systemic inflammation is a key driver of atherosclerotic cardiovascular disease and is increasingly recognized as a therapeutic target independent of traditional lipid lowering.”

Background: The Foundation of TRIUMPH-1

The new data build upon the foundational TRIUMPH-1 results announced on May 21, 2026. That study, which focused on adults with obesity or overweight without diabetes, reported that the 12-mg dose led to an average weight loss of 28.3% (70.3 Ib) at 80 weeks.² Most notably, a prespecified extension of that study showed that patients with a baseline BMI of 35 or higher who continued to 104 weeks achieved a staggering 30.3% (85 Ib) weight reduction.²

Goldman pointed out that this level of “sustained pharmacologic weight reduction” was “previously associated only with bariatric surgery.” This creates a new paradigm in which retatrutide may be positioned as “a potential escalation therapy beyond currently approved agents” within a “stepwise intensification model.”

The Pharmacist’s Role: Proactive Counseling and Safety Management

As frontline providers, pharmacists must be prepared to manage a safety profile that is generally consistent with the incretin class but contains unique nuances. Common adverse events (AEs) reported across the TRIUMPH trials included nausea, diarrhea, and vomiting, primarily occurring during the dose-escalation phase.^1,2

However, retatrutide is associated with a novel AE: dysesthesia/hyperesthesia (altered skin sensation). In TRIUMPH-1, this occurred in approximately 12.5% of the 12-mg group compared to 0.9% in the placebo group.² Goldman urged pharmacists to adopt an anticipatory counseling strategy.

“Inform patients that altered or enhanced skin sensation, such as tingling or heightened sensitivity to touch, may occur, is typically mild and transient, and did not lead to discontinuation in trials,” Goldman said. “Preemptive education will eliminate unnecessary alarm and premature discontinuation.”

Pharmacists should also reinforce the “start slow and go slow” titration schedule to mitigate gastrointestinal distress. For certain patients, such as older adults or those with significant gastrointestinal sensitivity, the 4-mg maintenance dose may be a viable option, as it still achieved nearly 20% weight loss in TRIUMPH-1 with a lower discontinuation rate than the higher doses.²

Conclusion: A Transformative Future Tool

With a biologics license application submission planned for the first quarter of 2027, retatrutide is nearing clinical reality.¹ Its ability to address obesity, T2D, and CVD risk simultaneously makes it “potentially transformative” for patients with complex comorbidities.

As the medical community awaits further data on obstructive sleep apnea and knee osteoarthritis pain, pharmacists should stay informed about the evolving clinical data package that supports retatrutide as a future cornerstone of cardiometabolic health management. Goldman concluded that although cardiovascular outcomes data are still pending, the pleiotropic effects on lipids and blood pressure position retatrutide as a significant step forward in treating the “complex biology” of obesity as a chronic neurometabolic disease.

REFERENCES
1. Lilly’s triple agonist, retatrutide, successful in two additional phase 3 obesity trials, delivering significant improvements in weight and A1C. News release. Lilly. July 23, 2026. Accessed July 23, 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional

2. Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal phase 3 obesity trial. News release. Lilly. May 21, 2026. Accessed July 23, 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss